This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mittler, J.
Right arrow Articles by Perelson, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mittler, J.
Right arrow Articles by Perelson, A. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2001, p. 1438-1443, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1438-1443.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Short-Term Measures of Relative Efficacy Predict Longer-Term Reductions in Human Immunodeficiency Virus Type 1 RNA Levels following Nelfinavir Monotherapy

John Mittler,1,2 Paulina Essunger,1 Geoffrey J. Yuen,3 Neil Clendeninn,3 Martin Markowitz,4 and Alan S. Perelson1,*

Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico 875451; Department of Microbiology, University of Washington, Seattle, Washington 981952; Agouron Pharmaceuticals, Inc., La Jolla, California 921373; and Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York 100164

Received 23 August 2000/Returned for modification 7 December 2000/Accepted 15 February 2001

We calculated the relative efficacy of treatment, defined as the rate of decline of virus levels in plasma during treatment relative to the rate of decline during highly potent combination therapy, in human immunodeficiency virus type 1 (HIV-1) patients treated for 56 days with different doses of the protease inhibitor nelfinavir. Relative efficacies based on the rate of decline of HIV-1 RNA levels in plasma over the first 14 to 21 days correlated with drug dose and viral load reduction by day 56. Calculation of relative treatment efficacies over the first 2 to 3 weeks of treatment can allow rapid assessment of new antiretroviral agents and dosing regimens, reducing the need to keep subjects in clinical trials on monotherapy for prolonged periods of time. Relative efficacy may also serve as a measure of treatment efficacy in patients in initiating established therapies.

* Corresponding author. Mailing address: MS-K710, Los Alamos National Laboratory, Los Alamos, NM 87545. Phone: (505) 667-6829. Fax: (505) 665-3493. E-mail: asp{at}lanl.gov.

Antimicrobial Agents and Chemotherapy, May 2001, p. 1438-1443, Vol. 45, No. 5
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.5.1438-1443.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Piliero, P. J. (2003). Early Factors in Successful Anti-HIV Treatment. J Int Assoc Physicians AIDS Care (Chic Ill) 2: 10-20 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»